Efficacy and tolerability of eplerenone and losartan in hypertensive black patients and white patients

Pratt, J. Howard; Flack, J.M.; Wright, Jackson T.; Patron, A.; Roniker, Barbara; Kleiman, Jay H.; Krause, Scott

doi:10.1016/s0895-7061(02)02850-9

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additional studies should be conducted to elucidate the optimal dosing regimen. In a randomized, controlled clinical trial, 64 eplerenone was compared with both losartan and placebo. The primary endpoint for the study was the mean change from baseline in trough DBP.…”

Section: Hypertensionmentioning

confidence: 99%

“…Interestingly, this study provides evidence that eplerenone may be more effective than losartan for the treatment of hypertension in African American patients. 64 Another study 65 examined eplerenone's effect on blood pressure when added to a treatment regimen containing either an ACE inhibitor or angiotensin receptor blocker (ARB). During a 4-week placebo run-in phase, 341 patients were withdrawn from all antihypertensive medications except a fixed-dose ACE inhibitor or ARB.…”

Section: Hypertensionmentioning

confidence: 99%

See 1 more Smart Citation

Eplerenone — A Novel Selective Aldosterone Blocker

Zillich

Carter

2002

Ann Pharmacother

View full text Add to dashboard Cite

show abstract

Section: Hypertensionmentioning

confidence: 99%

Section: Hypertensionmentioning

confidence: 99%

Eplerenone — A Novel Selective Aldosterone Blocker

Zillich

Carter

2002

Ann Pharmacother

View full text Add to dashboard Cite

show abstract

The Renin-Angiotensin System, Capri 2005

Alderman

Cífková

Cosentino

et al. 2005

High Blood Pressure & Cardiovascular Prevention

View full text Add to dashboard Cite

US Dietary Guidelines recommend sodium (Na) intake to be <2300 mg/day. The direct relationship of Na intake to blood pressure (BP) is established, but only a few inconsistent observational studies link Na with cardiovascular disease (CVD) outcomes. The Second National Health and Nutrition Examination Survey (NHANES II) and Mortality Study assessed dietary recall among 7154 subjects aged ≥30 years, free of heart disease, and not on low Na nor other special diets, nor who died within <6 months follow-up. Mean (± SE) age was 48 ± 0.3 years, mean weight 160 ± 0.4 pounds, 36% were smokers, 48% hypertensive. During a mean follow-up of 13.7 years (range 0.5-16.8) there were 584 CVD deaths. Hazard ratios (HR) and 95% CIs for Na and Na/calorie ratio (Na/KCal) were estimated with Cox regression models accounting for sampling and adjusting for CVD risk factors. Na as a continuous variable (per 1000mg) had a significant (p = 0.031) inverse association with CVD mortality (HR = 0.89, 95% CI: 0.81, 0.99), as did Na/KCal (HR = 0.80, 95% CI: 0.69, 0.94, p = 0.007). Dichotomising Na at <2300mg revealed significantly higher adjusted CVD risk (HR = 1.37, 95% CI: 1.03, 1.81, p = 0.033) associated with Na <2300mg. Results were consistent for all cause mortality (HR = 1.28, 95% CI: 1.1, 1.5, p = 0.003) and when stratified separately by weight, sex, smoking, or hypertensive status. The association of lower usual daily Na intake (as measured by a 24-hour dietary recall) with higher CVD mortality does not necessarily predict the consequences of change in Na intake. However, these robust data, reflecting experience of a large representative sample of the US population, indicating an inverse association of Na intake and cardiovascular mortality, do not support confidence that universal adherence to a dietary Na <2300mg will reduce CVD mortality or extend survival (figure 1, table I).

show abstract

The Resurrection of Spironolactone on Its Golden Anniversary

Futterman

Lemberg

2004

American Journal of Critical Care

View full text Add to dashboard Cite

Efficacy and tolerability of eplerenone and losartan in hypertensive black patients and white patients

Cited by 3 publications

References 0 publications

Eplerenone — A Novel Selective Aldosterone Blocker

Eplerenone — A Novel Selective Aldosterone Blocker

The Renin-Angiotensin System, Capri 2005

The Resurrection of Spironolactone on Its Golden Anniversary

Contact Info

Product

Resources

About